Primary outcomes
|
N
| |
N
| |
Mean systolic blood pressure, mmHg (SD) | 358a
| 137.2 (16.2) | 298b
| 139.0 (16.8) |
Mean LDL-cholesterol, mmol/l (SD) | 347c
| 2.6 (0.8) | 310d
| 2.6 (1.0) |
Secondary outcomes
| | | | |
Mean diastolic blood pressure, mmHg (SD) | 358 | 80.3 (10.2) | 298 | 80.6 (10.1) |
Blood pressure <140/90 mmHg | 358 | 214 (60) | 298 | 175 (59) |
LDL-cholesterol <2.5 mmol/l | 347 | 178 (51) | 310 | 168 (54) |
LDL-cholesterol <1.8 mmol/le
| 166 | 45 (27) | 163 | 58 (36) |
Smoking | 363 | 31 (9) | 311 | 30 (10) |
Mean BMI (SD) | 349 | 27.3 (5.2) | 300 | 27.7 (4.8) |
10
-year
CVD morbidity or mortality riskf
| | | | |
All patients, median (IQR) | 317 | 22.0 (11.7–36.4) | 267 | 24.0 (13.7–38.0) |
Patients with CVD, median (IQR) | 159 | 26.2 (17.9–38.5) | 144 | 27.8 (18.7–39.5) |
Patients without CVD, median (IQR) | 158 | 15.5 (5.4–31.9) | 123 | 18.7 (8.4–34.3) |
Healthy food habits
| | | | |
Vegetables >150–200 grams a day | 360 | 142 (39) | 294 | 99 (34) |
Fruits >200 grams a day | 354 | 214 (60) | 294 | 187 (64) |
Red meat <300 grams a week | 356 | 207 (58) | 286 | 155 (54) |
Fatty fish >1 a week | 358 | 244 (68) | 296 | 187 (63) |
Unhealthy fat products <3 a week & healthy fat products >3 a week | 352 | 121 (34) | 289 | 75 (26) |
Sweet & salty snacks <3 a week | 357 | 196 (55) | 295 | 157 (53) |
Table salt <3 a week | 360 | 335 (93) | 294 | 265 (90) |
Alcohol consumption, units a week, median (IQR) | 311 | 3 (0–7) | 292 | 2 (0–7) |
Physically activeg
| 303 | 230 (76) | 250 | 178 (71) |
Medication use
| | | | |
Patients with CVD
| | | | |
Antihypertensive drugs | 174 | 137 (79) | 160 | 121 (76) |
Lipid-lowering drugs | 174 | 139 (80) | 160 | 127 (79) |
Anticoagulants | 174 | 160 (92) | 160 | 146 (91) |
Patients without CVD
| | | | |
Antihypertensive drugs | 187 | 167 (89) | 149 | 126 (85) |
Lipid-lowering drugs | 188 | 52 (28) | 149 | 46 (31) |
GP as primary treating practitionerh
| 368 | 366 (99) | 314 | 307 (98) |
Consultations in general practice, median (IQR)i
| 361 | 6 (3–10) | 311 | 6 (3–10) |
Patient satisfaction (PREM) (1–5j), mean (SD) | 359 | 3.6 (0.7) | 283 | 3.5 (0.8) |
Recommendation score (0–10j), mean (SD) | 352 | 8.3 (1.3) | 275 | 8.2 (1.3) |
EQ-5D-5L index score (–0.45–1j), mean (SD) | 353 | 0.9 (0.1) | 290 | 0.8 (0.1) |
SF-12 Mental component (7.9–72.0j), mean (SD) | 353 | 53.9 (7.5) | 290 | 52.3 (9.3) |
SF-12 Physical component (5.2–64.7j), mean (SD) | 353 | 48.1 (9.2) | 290 | 46.7 (10.0) |
HADS Anxiety (0–7j), mean (SD) | 342 | 4.1 (3.3) | 286 | 4.5 (3.7) |
HADS Depression (0–7j), mean (SD) | 347 | 3.2 (3.0) | 283 | 3.9 (3.3) |
Newly developed CVDk
| 364 | 10 (3) | 311 | 10 (3) |
Newly developed comorbidityl
| 363 | 13 (4) | 311 | 12 (4) |
Mortality | 372 | 5 (1) | 318 | 3 (1) |